Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluate the efficacy and safety of Upadacitinib in adults with axial spondyloarthritis. The results were completed and posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2022-09-21